10 completed. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
Follow Tablets, Enteric-Coated: new trials by email Literature Review of Tablets, Enteric-Coated trials Research Report on Tablets, Enteric-Coated
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects. AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet - Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 21 | 2022-11-04 | 2024-03-04 |
| Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions DIRITHROMYCIN 500 MG ENTERIC COATED TABLET, DYNABAC 250 MG ENTERIC COATED TABLET - Healthy | Phase 1 | Completed | Pharmaceutical Research Unit, Jordan | 48 | 2014-12-01 | 2020-09-18 |
| Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions DIRITHROMYCIN 500 MG ENTERIC COATED TABLET, DYNABAC 250 MG ENTERIC COATED TABLET - Healthy | Phase 1 | Completed | Pharmaceutical Research Unit, Jordan | 48 | 2014-09-01 | 2020-09-18 |
| Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition DIRITHROMYCIN 500 MG ENTERIC COATED TABLET, DYNABAC 250 MG ENTERIC COATED TABLET - Healthy | Phase 1 | Completed | Pharmaceutical Research Unit, Jordan | 12 | 2014-06-01 | 2014-07-10 |
| Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition DYNABAC 250 MG ENTERIC COATED TABLET, DIRITHROMYCIN 500 MG ENTERIC COATED TABLET - Healthy | Phase 1 | Completed | Pharmaceutical Research Unit, Jordan | 12 | 2014-06-01 | 2014-07-10 |
| Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one, Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two, ASA 100 mg tablet - Ulcers, Duodenal and Gastric | Phase 1 | Completed | GlaxoSmithKline | 24 | 2013-05-16 | 2017-07-13 |
| Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one, Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two, ASA 100 mg tablet - Ulcers, Duodenal and Gastric | Phase 1 | Completed | GlaxoSmithKline | 24 | 2013-05-14 | 2017-07-13 |
| A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A GSK2190915 100mg milled tablet, [14C] radiolabelled GSK2190915 solution, GSK2190915 100mg milled tablet administered to the proximal small bowel. - Asthma | Phase 1 | Completed | GlaxoSmithKline | 14 | 2010-09-30 | 2017-08-03 |
| Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions Rabeprazole sodium 20 mg Delayed Release tablet - Healthy | Phase 1 | Completed | Torrent Pharmaceuticals Limited | 2013-11-21 | ||
| Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions Rabeprazole sodium 20 mg Delayed Release tablet - Healthy | Phase 1 | Completed | Torrent Pharmaceuticals Limited | 2013-11-21 |
Pharmaceutical Research Unit, Jordan (4) · GlaxoSmithKline (3) · Torrent Pharmaceuticals Limited (2) · AstraZeneca (1)
India (4) · Jordan (4) · United Kingdom (1) · United States (1)